Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Maternal Serum Osteopontin Levels in Pregnant Women Diagnosed With PPROM (OPN)

2 czerwca 2026 zaktualizowane przez: Erhan Okuyan,M.D, Batman Training and Research Hospital

Maternal Serum Osteopontin Levels in Pregnant Women Diagnosed With PPROM: A Prospective Case-Control Study

Preterm prelabor rupture of membranes (PPROM) is defined as the rupture of the fetal membranes prior to the onset of labor and before 37 weeks of gestation; it occurs in approximately 2-3% of all pregnancies and accounts for a significant proportion of preterm births .

Current data indicate that PPROM is not merely a clinical condition limited to membrane rupture; rather, it is a biological process associated with loss of structural integrity in the fetal membranes, an inflammatory-oxidative stress response, and cellular aging . The fetal membranes constitute a dynamic barrier that provides mechanical and immunological protection for the fetus throughout pregnancy .

There is limited data in the literature investigating the relationship between osteopontin and preterm birth. In particular, it has been reported that osteopontin levels may be higher in amniotic fluid samples collected during the second trimester from pregnant women who subsequently experienced spontaneous preterm birth . However, the changes in maternal serum osteopontin levels in cases of PPROM and the clinical significance of these changes remain unclear. Therefore, osteopontin levels may vary across different biological compartments and at different stages of pregnancy. To address this knowledge gap, the present study aimed to compare maternal serum osteopontin levels between pregnant women diagnosed with PPROM and those with term membrane rupture.

Przegląd badań

Status

Zakończony

Szczegółowy opis

This study was designed as a single-center, prospective, observational case-control study. The study protocol was approved by the Ethics Committee of the Faculty of Social and Humanities, Faculty of Science, Engineering, and Health Sciences at Batman University (Decision No: 2026/04-09; Date: 02.04.2026). Work began after the ethics committee approved the study. The research was conducted in accordance with the principles of the Declaration of Helsinki, and written informed consent was obtained from all participants.

Typ studiów

Obserwacyjny

Zapisy (Rzeczywisty)

71

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Lokalizacje studiów

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

  • Dorosły

Akceptuje zdrowych ochotników

Tak

Metoda próbkowania

Próbka prawdopodobieństwa

Badana populacja

Case Group (PPROM): Women were eligible for the PPROM group if they met all the following criteria: confirmed diagnosis of PPROM by clinical and/or ancillary tests, gestational age between 24+0 and 36+6 weeks, singleton pregnancy, age 18 years or older, and provision of written informed consent.

Control Group (Term ROM): Women were included in the control group if they met all the following criteria: rupture of membranes at term (gestational age ≥37+0 weeks), singleton pregnancy, age 18 years or older, provision of written informed consent, absence of signs of active infection, and no history of additional systemic diseases.

Opis

Inclusion Criteria:

  • For the case group (PPROM):
  • Gestational age between 24+0 and 36+6 weeks
  • Singleton pregnancy
  • Age ≥18 years
  • Provision of written informed consent
  • Confirmed diagnosis of PPROM by clinical and/or ancillary tests
  • For the control group (term rupture of membranes):
  • Gestational age ≥37+0 weeks
  • Rupture of membranes
  • No signs of active infection
  • Singleton pregnancy
  • Age ≥18 years
  • Provision of written informed consent
  • No history of additional systemic diseases

Exclusion Criteria (for both groups):

  • Multiple pregnancy
  • Major fetal anomaly
  • Fetal distress
  • Intrauterine growth restriction (IUGR)
  • Clinical chorioamnionitis
  • Systemic infection
  • Autoimmune or chronic inflammatory disease
  • Smoking
  • History of malignancy
  • Gestational trophoblastic disease
  • Diabetes mellitus
  • Preeclampsia
  • Other serious obstetric complications

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

Kohorty i interwencje

Grupa / Kohorta
Interwencja / Leczenie
PRETERM LABOR (1)
The study group included pregnant women with a diagnosis of preterm premature rupture of membranes (PPROM) confirmed by clinical and/or diagnostic tests. The diagnosis was confirmed by observing the discharge of amniotic fluid from the cervical os during a sterile speculum examination and, when necessary, by confirmatory diagnostic tests. The study included pregnant women without additional systemic diseases and with blood pressure measurements within the normal range.

At the time of diagnosis, 5 mL venous blood samples were collected from all participants for biochemical analysis. The samples were centrifuged at 3,000 rpm for 10 minutes to separate the serum, which was then stored at -80°C until analysis. Serum osteopontin levels were measured using a sandwich enzyme-linked immunosorbent assay (ELISA) kit (Human Osteopontin ELISA Kit, Cat. No: E1525Hu, BT Laboratory, China) in accordance with the manufacturer's protocol.

This kit has been developed for the quantitative determination of osteopontin levels in serum, plasma, and other biological fluids. The assay principle is based on the pre-coating of microplate wells with an antibody specific to human SPP1. The osteopontin present in the samples was incubated with a biotinylated secondary antibody and a streptavidin-horseradish peroxidase (HRP) complex after binding to this antibody. Following the washing steps, a substrate solution was added, and the resulting color reaction was stopped with an ac

Inne nazwy:
  • OSTEOPONTİN
Control /Term labor (2)
The control group included pregnant women with a singleton pregnancy who experienced membrane rupture at 37 weeks + 0 days of gestation or later, had no signs of active infection and no history of additional systemic diseases. It was confirmed that none of these cases had a history of membrane rupture prior to the 37th week of gestation. The control group was selected from volunteers who met the eligibility criteria at the time of their admission to the delivery ward, and written informed consent was obtained after they were informed about the study.

At the time of diagnosis, 5 mL venous blood samples were collected from all participants for biochemical analysis. The samples were centrifuged at 3,000 rpm for 10 minutes to separate the serum, which was then stored at -80°C until analysis. Serum osteopontin levels were measured using a sandwich enzyme-linked immunosorbent assay (ELISA) kit (Human Osteopontin ELISA Kit, Cat. No: E1525Hu, BT Laboratory, China) in accordance with the manufacturer's protocol.

This kit has been developed for the quantitative determination of osteopontin levels in serum, plasma, and other biological fluids. The assay principle is based on the pre-coating of microplate wells with an antibody specific to human SPP1. The osteopontin present in the samples was incubated with a biotinylated secondary antibody and a streptavidin-horseradish peroxidase (HRP) complex after binding to this antibody. Following the washing steps, a substrate solution was added, and the resulting color reaction was stopped with an ac

Inne nazwy:
  • OSTEOPONTİN

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Maternal Serum Osteopontin Concentration
Ramy czasowe: 48 hours

Description: Concentration of osteopontin (ng/mL) measured in maternal serum using a commercially available enzyme-linked immunosorbent assay (ELISA) kit (e.g., Human Osteopontin ELISA Kit, manufacturer name and catalog number to be specified). Blood samples are collected at the time of diagnosis of PPROM or term membrane rupture, within 48 hours before delivery.

Unit of Measure: ng/mL (nanograms per milliliter) Time Frame: 48 hours (from diagnosis to sample collection) Reporting Metric: Mean osteopontin concentration (with standard deviation) will be reported for each group (PPROM and term membrane rupture). Between-group comparison will be performed using an appropriate statistical test (e.g., independent t-test or Mann-Whitney U test).

48 hours

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Rzeczywisty)

9 kwietnia 2026

Zakończenie podstawowe (Rzeczywisty)

12 maja 2026

Ukończenie studiów (Rzeczywisty)

12 maja 2026

Daty rejestracji na studia

Pierwszy przesłany

21 maja 2026

Pierwszy przesłany, który spełnia kryteria kontroli jakości

2 czerwca 2026

Pierwszy wysłany (Rzeczywisty)

4 czerwca 2026

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

4 czerwca 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

2 czerwca 2026

Ostatnia weryfikacja

1 czerwca 2026

Więcej informacji

Terminy związane z tym badaniem

Plan dla danych uczestnika indywidualnego (IPD)

Planujesz udostępniać dane poszczególnych uczestników (IPD)?

NIE

Opis planu IPD

IPD will not be shared as participants consented solely to the use of their data for journal publication, not to broader individual-level data sharing."

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Nie

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Badania kliniczne na Przedwczesny poród

Badania kliniczne na SERUM OSTEOPONTİN

Subskrybuj